MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

Inclusion criteria for subproject MCS-2 * Age ≧ 40 years old. * Not being treated for BPH or LUTS with Alpha-blocker, anti-cholinergics, 5-alpha reductase inhibitors, or hormonal agents. * PSA≦4 ng/ml within 4 weeks of V1 and no pathologically-proven prostate cancer. * No known malignancy, except cancers without signs of recurrence for \> 5 years and no need for further anti-cancer treatment. * AST/ALT≦3X UNL. * creatinine≦3X UNL. * Subjects who sign the informed consent form. Exclusion criteria * Subjects' LUTS are not BPH-related but are associated with such conditions as urethral stricture, prostatitis, neurogenic bladder, or pelvic treatment procedures. * Have been treated with pelvis irradiation or pelvic surgery. * Plan to undergo any invasive procedures within the study period, such as, prostate surgery, prostate biopsy, cystourethroscopy, pelvic surgery, laparotomy, or any procedures needing urethral catheterization. * Participating in another investigational agent study in the past 12 weeks or are going to do so during the study period. * Active infection or inflammation. * Considered ineligible by the investigators. Inclusion criteria for subproject MCS-3 * Age≧40 years old. * The alpha-blocker dosage used should be as high as subjects can tolerate. * No known malignancy, except cancers without signs of recurrence for \> 5 years and no need for further anti-cancer treatment. * PSA≦10.0 ng/ml without pathologically-proven prostate cancer or other cancers. Prostate biopsy is mandatory \> 12 weeks before screening, if PSA is≧4 ng/ml to rule out prostate cancer. * AST/ALT≦3X UNL. * Creatinine≦3X UNL. * Subjects who sign the informed consent form. Exclusion criteria * Subjects' LUTS are not BPH-related but associated with such conditions as urethral stricture, prostatitis, neurogenic bladder, or pelvic treatment procedures. * Subjects who have been treated with pelvis irradiation or pelvic surgery. * PSA \> 10.0 ng/ml, abnormal DRE of the prostate or any suspicion of prostate malignancy. However, those who have a negative prostate biopsy are allowed. * Active infection or inflammation. * Considered ineligible by the investigators.